Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_assertion type Assertion NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_head.
- NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_assertion description "[The Mdm2 inhibitor nutlin-3 was evaluated alone and in combination with cisplatin in a panel of germ cell tumour (GCT)-derived cell lines (embryonal carcinomas, being the nonseminomatous stem-cell component) with wild-type (NT2 and 2102EP cells) and mutant (NCCIT cells) p53 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_provenance.
- NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_assertion evidence source_evidence_literature NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_provenance.
- NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_assertion SIO_000772 19560254 NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_provenance.
- NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_assertion wasDerivedFrom befree-2016 NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_provenance.
- NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_assertion wasGeneratedBy ECO_0000203 NP747860.RABXMEK_ll-UEckzEpwGSvaRMe4hWp_GhaTea7FfomhnU130_provenance.